Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463788
Status:
COMPLETED
Last Update Posted:
2014-02-13
First Post:
2007-04-19
Brief Title:
Cetuximab and Cisplatin in the Treatment of Triple Negative Estrogen Receptor ER Negative Progesterone Receptor PgR Negative and Human Epidermal Growth Factor Receptor 2 HER2 Negative Metastatic Breast Cancer
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
EMR 200027-051
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None